Pyxis Oncology Inc. (PYXS) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Pyxis Oncology Inc. (PYXS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.43

-0.01 (-0.69%)

At close: Jan 15, 2025, 5:13 PM

undefined% (undefined)

Bid	1.42
Market Cap	85.04M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.06
PE Ratio (ttm)	-1.35
Forward PE	n/a
Analyst	Buy

Ask	1.43
Volume	392,873
Avg. Volume (20D)	1,339,288
Open	1.45
Previous Close	1.44
Day's Range	1.40 - 1.50
52-Week Range	1.40 - 6.85
Beta	undefined

About PYXS

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therap...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 8, 2021

Employees 54

Stock Exchange NASDAQ

Ticker Symbol PYXS

Website https://www.pyxisoncology.com

Analyst Forecast

According to 8 analyst ratings, the average rating for PYXS stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 599.30% from the latest price.

Buy 87.50%

Hold 12.50%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 month ago · Source

-45.03%

Pyxis Oncology shares are trading lower after Will... Unlock content with Pro Subscription

1 month ago · Source

-8.17%

Pyxis Oncology shares are trading higher after the company announced PYX-201 clinical Phase 1 part 1 data.

News

1 month ago · seekingalpha.com

Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with...

1 month ago · benzinga.com

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns

On Wednesday, Pyxis Oncology, Inc. PYXS released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors.

2 months ago · benzinga.com

Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside

Stephens has initiated coverage on Pyxis Oncology Inc PYXS, highlighting the company's technology platform aimed at developing next-gen antibody-drug conjugates (ADCs) with enhanced potency, stability...